Læknablaðið - 15.11.2003, Page 14

Cipralex escitalopram
- rökrétt framþróun frá Cipramirdtalopram
• Cipralex® skjót linun þunglyndiseinkenna12 3
• Cipralex® 10-20 mg hefur marktækt betri verkun en
Cipramil® 20-40 mg - einnig í alvarlegu þunglyndi
(Creining á sameiginlegum niðurstöðum (pooled data) 3 lyfleysustýrðra rannsókna*)1
• Cipralex® þolist vel með aukaverkanir svipaðar
og af Cipramil®4
• Cipralex® er sértækasta SSRI lyfið5
* = Betri verkun samkvæmt MADRS skala í viku 1 og 8, við alvarlegu þunglyndi í viku
1,6 og 8 (OC-greining).
Ljm Cipralex
I W ^ I escitalopram
Lundbeck Pharma A/S
Umboð á íslandi: Austurbakki hf.
Köllunarklettsvegi 2 • 104 Reykjavík
Sími 563 4000- Fax 563 4090
www.austurbakki.is
Austurbakki
Sérlyfjatexti á bls. 908
Heimildir:
1. Wade A, Lemming OM, Hedegaard KB. EscitalopramlO mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol
2002; 17: 95-102.
2. Burke WJ, Gergel I, Bose A. Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients. J Clin Psychiatry 63:4, April 2002.
3. Gorman JM, Korotzer A, Su G. Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials. CNS
Spectrums, April 2002, volume 7 (suppl 1): 40-44.
4. Montgomery SA et al. Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model. Pharmacology & Toxicology 2001, 88, 282-286.
5. Owens MJ, Knight DL, Nemeroff CB. Second-Generation SSRIs: Human Monoamine Transporter Binding Profile of Escitalopram and R-Fluoxetine. Biol Psychiatry 2001;
50: 345-350.